Monteiro Beatriz P, Lambert Cedric, Bianchi Elena, Genevois Jean Pierre, Soldani Giulio, Troncy Eric
Department of Biomedical Sciences, GREPAQ (Groupe de recherche en pharmacologie animale du Québec), Faculty of Veterinary Medicine - Université de Montréal, 3200 Sicotte Street, Saint-Hyacinthe, QC, J2S 2M2, Canada.
Department of Companion Animals, Vet-Agro Sup, Lyon, France.
BMC Vet Res. 2019 Jun 25;15(1):213. doi: 10.1186/s12917-019-1960-3.
This study aimed to evaluate the safety and efficacy of reduced-dosage ketoprofen with or without tramadol in dogs. Five healthy dogs receiving standard-dosage ketoprofen (2 mg/kg SC, then 1 mg/kg PO daily) comprised Group A. Twenty dogs with osteoarthritis were randomized to receive reduced-dosage ketoprofen (0.5 mg/kg SC once; 0.25 mg/kg PO daily) alone (Group B) or in combination with tramadol (5 mg/kg/day PO) (Group C). Treatments were administered for 28 days. Platelet aggregation time (PAT), gastrointestinal (GI) endoscopy and glomerular filtration rate (GFR) were performed up to 60 days after treatment initiation. Pain was scored using a validated clinical metrology instrument up to D120. Data were analyzed with general linear mixed model for repeated measures (α = 0.05).
PAT was not different between groups but was increased with time for all groups. GI lesion scores were higher in Group A than Groups B and C (day 28; P = 0.005) and were increased with time for Group A (P = 0.005). GFR was lower in Group A than Groups B and C (day 28; P < 0.01) and were decreased with time for group A (P < 0.001). Standard-dosage ketoprofen administration resulted in clinically relevant adverse effects. Pain score decreased in both treated groups (B and C) from D0 to D28. Need of rescue analgesia from D29 to D120 was higher in Group B than in Group C (P = 0.039).
The long-term safety profile of reduced-dosage ketoprofen is similar whether the drug is administered alone or in combination with tramadol to dogs with osteoarthritis. Analgesic efficacy of the combination looks attractive.
本研究旨在评估减量酮洛芬单独或联合曲马多对犬的安全性和有效性。5只接受标准剂量酮洛芬(2mg/kg皮下注射,然后1mg/kg口服每日一次)的健康犬组成A组。20只骨关节炎犬被随机分为单独接受减量酮洛芬(0.5mg/kg皮下注射一次;0.25mg/kg口服每日一次)(B组)或联合曲马多(5mg/kg/天口服)(C组)。治疗持续28天。在治疗开始后60天内进行血小板聚集时间(PAT)、胃肠道(GI)内镜检查和肾小球滤过率(GFR)测定。使用经过验证的临床计量仪器对疼痛进行评分,直至第120天。采用重复测量的一般线性混合模型分析数据(α = 0.05)。
各组间PAT无差异,但所有组的PAT均随时间增加。A组的GI病变评分高于B组和C组(第28天;P = 0.005),且A组随时间增加(P = 0.005)。A组的GFR低于B组和C组(第28天;P < 0.01),且A组随时间降低(P < 0.001)。标准剂量酮洛芬给药导致临床相关不良反应。两个治疗组(B组和C组)的疼痛评分从第0天到第28天均降低。从第29天到第120天,B组的救援镇痛需求高于C组(P = 0.039)。
减量酮洛芬单独或联合曲马多给药于骨关节炎犬时,其长期安全性相似。联合用药的镇痛效果颇具吸引力。